1. WHWK will present at the Jefferies 2025 Global Healthcare Conference. 2. CEO Dave Lennon will cover company advancements on June 4, 2025. 3. Whitehawk's ADC portfolio aims to overcome cancer treatment challenges. 4. Advanced technologies are applied for improved oncology therapeutics. 5. Webcast of the presentation will be available post-event for 30 days.
Whitehawk's participation in a major healthcare conference boosts visibility and investor interest. Historically, such events can lead to positive stock performance as seen with similar biotech companies.
The conference provides a platform to attract investor interest and validate WHWK’s innovations. Engaging discussions at high-profile events often lead to immediate topical relevance, thus influencing stock behavior positively.
The event's timing is close, with immediate media attention impacting WHWK’s stock shortly after the conference.
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved ADC cancer treatments, announced today its presentation at the Jefferies 2025 Global Healthcare Conference, taking place June 3-5, 2025, in New York City, NY. Dave Lennon, PhD, President and CEO, will present a company overview on Wednesday, June 4, 2025, from 2:00-2:30 PM ET.
A live webcast of the fireside chat can be accessed by visiting the Whitehawk Therapeutics IR website and will be available for replay for approximately 30 days following the event.
Whitehawk Therapeutics is an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved cancer treatments. Whitehawk's advanced three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers. These assets are in-licensed from WuXi Biologics under an exclusive development and global commercialization agreement. More information on the Company is available at www.whitehawktx.com and connect with us on LinkedIn.
Contact: info@whitehawktx.com
SOURCE Whitehawk Therapeutics, Inc.